Alma TED Hair Treatment: Who Is a Good Candidate — The Norwood-to-Ludwig Staging Guide That Tells You If Your Hair Loss Qualifies Before You Book

Introduction: Why “Early to Moderate Hair Loss” Isn’t Enough of an Answer

Anyone researching Alma TED runs into the same frustrating phrase again and again: “ideal for early to moderate hair loss.” It sounds reassuring, but it leaves the most important question unanswered. What exactly counts as “moderate”? Where is the line between qualifying and not qualifying? Booking a consultation on the strength of a vague description feels like a leap of faith.

Alma TED is an FDA-cleared, needle-free treatment that uses ultrasound waves and gentle air pressure to deliver a growth factor and peptide serum into the scalp without injections, incisions, or anesthesia. It is a genuinely promising option, but it is not right for everyone, and the difference between a strong candidate and a poor one comes down to specific, measurable factors.

This article closes that gap. By the end, readers will be able to map their own hair loss to a clinical staging scale (Norwood for men, Ludwig for women) and understand, with real specificity, whether Alma TED is likely to work for them. With more than 80 million men and women in the United States experiencing hair loss, an accurate self-assessment before booking is genuinely valuable.

The dimensions that follow cover staging scale position, hair loss type, follicle dormancy timeline, contraindications, and needle phobia as a legitimate candidacy factor. One note on honesty: most of the clinical data on Alma TED is currently manufacturer-sponsored, and large-scale independent randomized controlled trials remain limited as of 2026. That context matters and will be treated transparently throughout.

How Alma TED Works: The Biology That Determines Who Benefits

Alma TED relies on TransEpidermal Delivery. Ultrasound waves combined with air pressure temporarily open microscopic channels in the outer layer of the scalp, allowing a growth factor and peptide serum to penetrate deeply without any needle ever touching the skin.

The single most important fact about candidacy is this: Alma TED stimulates existing hair follicles. It cannot create new follicles where none remain. That is the foundational reason follicle presence is the non-negotiable requirement for every candidacy decision in this guide.

The biology behind this involves the Wnt/β-Catenin signaling cascade in hair follicle stem cells, widely regarded as the dominant pathway for new hair formation. When growth factors reach viable follicles, they help push those follicles back toward active growth. When the follicle is gone, there is nothing left to signal.

This is why the distinction between miniaturized follicles and absent follicles governs everything. A miniaturized follicle is weakened and producing thin, short hair, but it is still present and potentially responsive. An absent follicle has been permanently lost and will not respond to any stimulation-based treatment.

The standard protocol is three sessions spaced roughly one month apart, with maintenance every 6 to 12 months. Unlike PRP, Alma TED does not trigger a post-treatment shedding phase (shock loss), which makes the early experience far less alarming for patients.

The Norwood Scale for Men: Which Grades Qualify and Which Don’t

The Hamilton-Norwood Scale is the clinical standard for classifying male pattern baldness. It runs from Grade I (no significant loss) through Grade VII (the most advanced, with only a horseshoe band of hair remaining around the sides and back).

Clinical study eligibility for Alma TED centered on Norwood Grades II through V, with Grades VI and VII explicitly excluded in published white paper criteria. That single line resolves most of the confusion.

• Grade I typically does not qualify because hair loss is too minimal for measurable impact. Preventive use may be discussed with a provider, but it is not the primary indication.
• Grades II through V qualify because follicles in the affected areas are miniaturized and weakened but still present. They remain biologically capable of responding to growth factor stimulation.
• Grades VI and VII do not qualify because follicles in the affected regions have been permanently lost. There is no biological substrate for the serum to reactivate, and a hair transplant consultation becomes the more appropriate next step.

Age and stage interact in important ways. A 24-year-old at Norwood III faces very different urgency than a 50-year-old at the same grade. Younger men with rapidly progressing loss often benefit most from combining Alma TED with stabilizing medications such as finasteride and minoxidil, and they should discuss the full picture with a specialist.

For a quick self-check: Grade II shows slight recession at the temples; Grade III shows deeper temple recession or early crown thinning; Grade IV shows more pronounced frontal and crown loss with a bridge of hair between them; and Grade V shows those areas enlarging as the bridge narrows. For a deeper look at what to expect at this stage, Norwood Scale 5 hair transplant realistic expectations offers useful context on the boundary between non-surgical and surgical candidacy.

The Ludwig Scale for Women: Stages I and II Are the Target Window

Female pattern hair loss follows a different pattern and uses the Ludwig Scale. Stage I involves diffuse thinning at the crown, Stage II shows a more pronounced widening of the part with visible scalp, and Stage III represents advanced thinning across the top of the head.

Alma TED is most effective for women at Ludwig Stages I and II, where follicles are still present but may be dormant or producing thinner, weaker strands. These are the stages where follicles remain viable and growth factors can signal them back into the active growth (anagen) phase.

Stage III yields limited benefit for the same reason Norwood VI and VII do in men: many follicles have been permanently lost, reducing the biological surface area available for a treatment response.

Female hair loss is often diffuse rather than patterned, which can make self-staging harder. The Ludwig Scale is a helpful guide, but confirming a stage with a specialist is important. With 30 million women in the United States affected by androgenetic alopecia, accurate candidacy guidance for this audience is essential.

Self-assessment hallmarks: Stage I shows slight thinning where the part appears a little wider than it used to. Stage II shows a clearly widened part with scalp visible under direct light.

The 10-Year Dormant Follicle Threshold: Why Timing Is a Candidacy Factor

Staging is only half the story. How long a person has been at their current stage matters just as much.

Hair follicles dormant for more than roughly 10 years are significantly less likely to respond to stimulation-based treatments. Follicles dormant beyond that window are less likely to change with treatment, which is why early intervention is always preferable.

The biology explains why. Prolonged dormancy allows miniaturization to advance toward fibrosis, where the follicle becomes surrounded by scar-like tissue that blocks reactivation signals even when growth factors are delivered.

This creates a practical candidacy question: not just “what stage am I?” but “how long have I been here?” Recent progression is a more favorable sign than long-standing stable loss. A patient who noticed thinning two or three years ago at Norwood III is a stronger candidate than someone who has held at Norwood III for 12 years without treatment.

The 10-year mark is a probability curve, not a hard cutoff, but the message is consistent: Alma TED is most powerful as an early intervention tool, not a rescue treatment for long-neglected hair loss.

Hair Loss Type Matters: How Different Conditions Respond to Alma TED

Not all hair loss is the same, and response to Alma TED varies meaningfully by underlying cause.

Androgenetic Alopecia (Male and Female Pattern Hair Loss)

Alma TED is FDA-cleared specifically for androgenetic alopecia, making this the best-evidenced indication. The condition is driven by DHT, which progressively miniaturizes follicles, shortening the growth cycle until hairs become finer and shorter and eventually stop appearing.

Realistic expectations matter here. Androgenetic alopecia is chronic and progressive. Alma TED can slow progression, improve density, and strengthen existing hair, but it does not cure the underlying hormonal sensitivity. That is precisely why combining Alma TED with finasteride or minoxidil is a strong profile: the medication addresses the hormonal driver while TED delivers growth factors to the follicle. For a comprehensive look at where this treatment fits among current options, androgenetic alopecia treatment latest advances 2026 provides useful context.

In the manufacturer-sponsored study of 50 patients reported by Alma Lasers, 89% observed visible improvement in hair density after three treatments.

Telogen Effluvium (Stress-Related Shedding)

Telogen effluvium is a temporary shift of a large number of follicles into the resting phase at once, triggered by physical or emotional stress, illness, surgery, or nutritional deficiency.

This type often responds well because the follicles are not damaged or miniaturized; they are simply stalled. Growth factor delivery can help signal re-entry into active growth, and these patients may see faster early improvement than androgenetic alopecia patients because the follicle architecture is intact.

One important nuance: if an ongoing trigger persists (active nutritional deficiency or uncontrolled thyroid disorder), treating the root cause is essential alongside or before Alma TED. An integrative pre-treatment evaluation covering thyroid function, iron and ferritin, vitamin D, and hormones can identify correctable contributors. Understanding how this condition differs from pattern hair loss is important; telogen effluvium vs androgenetic alopecia differences breaks down the key distinctions.

Postpartum Hair Loss

During pregnancy, elevated estrogen prolongs the growth phase. After delivery, estrogen drops sharply and a large cohort of follicles enters the resting phase together, causing dramatic shedding typically 2 to 4 months postpartum.

These patients are highly motivated and time-sensitive candidates. They know exactly when the loss began, the cause is well defined, and the follicles are structurally healthy, so growth factor stimulation can accelerate a return to normal cycling.

A critical note: Alma TED is contraindicated during pregnancy itself due to lack of safety data, and breastfeeding patients should discuss timing with their provider. Postpartum loss usually self-resolves within 6 to 12 months, and Alma TED may accelerate recovery and shorten the peak shedding period.

Hormonal Thinning (Perimenopause and Menopause)

Declining estrogen and progesterone reduce the protective effect these hormones have on follicles, allowing androgenic effects to become more pronounced and producing diffuse thinning often classified on the Ludwig Scale.

This is a strong candidacy group: loss is typically diffuse, follicles are usually still present at Ludwig Stage I or II, and the condition is responsive to growth factor support. It often overlaps with androgenetic alopecia, since a genetic predisposition becomes clinically visible as hormonal protection fades. Hormonal evaluation with a gynecologist or endocrinologist can significantly improve outcomes. The non-invasive, no-downtime nature of Alma TED makes it especially appealing to this demographic.

Contraindications Explained: Why Each Condition Disqualifies a Patient at a Biological Level

Understanding why a condition disqualifies a patient supports informed decisions and a more productive consultation.

Pregnancy

There is no safety data on ultrasound-based transdermal delivery of growth factor serums during pregnancy, so the precautionary principle applies. This differs from diagnostic obstetric ultrasound; therapeutic scalp ultrasound and the serum ingredients have not been studied for fetal safety. Pregnant patients should wait until after delivery and, if breastfeeding, consult their provider about timing.

Active Scalp Infections or Severe Psoriasis

The same mechanism that opens channels to deliver serum could also allow pathogens from an active infection to penetrate more deeply, potentially worsening or spreading it. With severe psoriasis, active inflammation disrupts the scalp environment the treatment depends on. This is usually a “treat first, then qualify” situation, making it a temporary rather than permanent disqualification.

Scarring Alopecias (e.g., Lichen Planopilaris, Frontal Fibrosing Alopecia)

Scarring alopecias permanently destroy follicles through inflammatory fibrosis, replacing the follicular unit with scar tissue. Unlike androgenetic alopecia, there is nothing left to reactivate. Alma TED cannot reverse fibrosis. Some patients may have non-scarred areas that could benefit, but a specialist must evaluate the extent of scarring, and a dermatologist specializing in these conditions should manage the disease first.

Implanted Electronic Devices Near the Scalp

Ultrasound energy can interfere with implanted electronic devices such as cochlear implants or certain neurostimulators near the treatment area. This is a safety-based contraindication rather than a biological one. Patients with any such devices in or near the head and neck should disclose them so proximity and risk can be assessed case by case.

Known Malignancy in the Treatment Area

Delivering growth factors and stimulating cellular activity in an area with active malignancy could theoretically promote tumor growth or interfere with cancer treatment. Patients with a history of scalp or skin cancer need confirmed clearance from their oncologist first. This applies to the treatment area specifically; unrelated malignancies elsewhere should still be disclosed in the full medical history.

Immune System Disorders

Some immune disorders, particularly autoimmune alopecia such as alopecia areata, involve the immune system attacking follicles directly. Delivering growth factors without addressing that attack may be ineffective. Mild alopecia areata may show some response, but it typically requires a multi-modal immunomodulatory approach rather than Alma TED alone. Patients on immunosuppressive therapy may also have altered healing. These patients are not universally disqualified but require specialist evaluation.

Needle Phobia as a Legitimate Candidacy Criterion: Alma TED as a PRP Alternative

Needle phobia is a real, clinically significant barrier. A meaningful share of the population experiences needle anxiety severe enough to avoid medical care entirely, making it a genuine healthcare access issue rather than a trivial preference.

PRP has long been a common non-surgical hair restoration option because it delivers concentrated growth factors to the scalp with solid clinical support. The catch is that it requires multiple scalp injections per session, a real barrier for needle-averse patients.

Alma TED offers a clinically sound alternative, delivering a comparable growth factor and peptide payload without any needles. Since it does not use needles like platelet-rich plasma (PRP), it can be a good option for those who prefer to avoid them.

The experience differs sharply: no injections, no blood draw, no anesthesia, no downtime. The two approaches differ in source (PRP uses the patient’s own platelet-derived growth factors; Alma TED uses a standardized serum), and the best choice depends on individual biology, preference, and candidacy. For a closer look at how growth factor-based treatments compare, stem cell hair treatment vs PRP difference explores the distinctions in detail.

The ideal needle-phobic candidate is someone at Norwood II to V or Ludwig I to II, with androgenetic alopecia or telogen effluvium, who has avoided treatment specifically because of needle aversion. Alma TED can also serve as a bridge, letting patients build confidence before reassessing more involved options later.

Combination Therapy Candidates: Who Benefits Most From Adding Alma TED to an Existing Regimen

Patients already using finasteride, minoxidil, or low-level light therapy who want an in-office non-invasive booster are excellent combination candidates.

The synergy is straightforward: finasteride reduces DHT, minoxidil increases blood flow to follicles, and Alma TED delivers growth factors and peptides directly. Each mechanism is complementary, not redundant. TED may work well alongside FDA-approved medications like finasteride or minoxidil.

Patients who have plateaued on medication are especially strong candidates. If finasteride or minoxidil has stabilized loss but not delivered the density hoped for, adding Alma TED may provide the extra stimulation needed. For patients who are not needle-phobic, Alma TED can even be combined with PRP to maximize growth factor delivery. It is also a valuable maintenance tool for hair transplant patients who want to protect their non-transplanted native hair. Combination decisions belong in a consultation with a specialist who can assess the full picture. Patients curious about how minoxidil and finasteride together results compare to adding an in-office treatment will find that page a useful companion read.

The Integrative Pre-Treatment Evaluation: What to Check Before a Consultation

Bloodwork matters because several systemic conditions can cause or worsen hair loss and directly affect how well Alma TED works. Treating the surface without addressing the underlying driver limits results.

Key factors to evaluate include:

• Thyroid function (hypothyroidism is a common, treatable cause of diffuse loss)
• Iron and ferritin levels (iron deficiency is strongly linked to telogen effluvium, especially in women)
• Vitamin D status (connected to follicle cycling)
• Hormonal panels (androgens, estrogen, progesterone)

A consultation should confirm candidacy and identify treatable contributing factors such as thyroid function, iron status, nutrient needs, and hormone-related patterns. Patients who arrive with recent bloodwork are better positioned for a productive conversation. Scalp health is also a prerequisite, so active dandruff, seborrheic dermatitis, or inflammation should be managed first. No one needs to complete all testing before booking; a specialist can order appropriate tests during the evaluation.

What If You Don’t Qualify? Constructive Next Steps for Non-Candidates

Acknowledging that Alma TED is not right for everyone, and pointing to real alternatives, reflects a focus on outcomes rather than a sale.

• Advanced male pattern baldness (Norwood VI–VII): a hair transplant consultation is the appropriate step. FUE or FUT can relocate donor follicles from the back and sides to restore areas where follicles are permanently absent.
• Advanced female pattern loss (Ludwig Stage III): a consultation to discuss surgical options or scalp micropigmentation for the appearance of density is appropriate.
• Scarring alopecia: a dermatologist specializing in inflammatory scalp conditions should manage the disease and halt progression before any restoration approach.
• Temporary disqualifications (active infection, pregnancy, scalp inflammation): these patients are future candidates, not permanent non-candidates. Resolving the condition and returning for reassessment is the appropriate path.
• Systemic contributors (thyroid dysfunction, iron deficiency): correcting the underlying issue may resolve or improve hair loss and make Alma TED more effective or even unnecessary.

Ultimately, a professional consultation with a scalp examination and medical history review is the only way to confirm candidacy with certainty.

Quick-Reference Candidacy Summary: Is Alma TED the Right Fit?

Likely candidate indicators:

• Norwood Grade II–V (men) or Ludwig Stage I–II (women)
• Hair loss duration under 10 years in the affected area
• Androgenetic alopecia or telogen effluvium
• Postpartum or hormonal (perimenopause/menopause) thinning
• Needle phobia preventing PRP
• Already on medication and seeking an in-office complement
• No active scalp infections or contraindicated conditions

Likely non-candidate indicators:

• Norwood Grade VI–VII or Ludwig Stage III
• Scarring alopecia
• Active scalp infection or severe psoriasis
• Pregnancy
• Implanted electronic devices near the scalp
• Active malignancy in the treatment area

Self-assessment with staging scales is a useful starting point, but professional evaluation is required to confirm candidacy, since scales have limits and causes often overlap. On the evidence: results are promising, with studies reporting 96 to 98% of patients experiencing reduced shedding and increased growth after three treatments, though most data is manufacturer-sponsored and independent large-scale RCTs remain limited as of 2026.

Conclusion: The Right Candidate Gets the Best Results

Alma TED is a genuinely effective, well-tolerated, needle-free option for the right patient. “The right patient,” however, is a specific clinical profile, not a vague description.

The pillars are clear: follicle presence (confirmed by staging position), hair loss type (androgenetic alopecia and telogen effluvium are the strongest indications), dormancy timeline (earlier is better), absence of contraindications, and unique value for needle-phobic patients. Just as important is the honest limitation: Alma TED is not a cure for androgenetic alopecia and cannot help where follicles have already been permanently lost.

Understanding one’s own hair loss stage and type before a consultation produces a more informed patient, better treatment decisions, and ultimately better outcomes. The natural next step is a professional consultation where staging can be confirmed, contributing factors evaluated, and a personalized plan developed. A hair restoration procedures decision framework can also help patients think through the full range of options before that conversation.

Ready to Find Out If Alma TED Is Right for You? Schedule a Consultation at Hair Transplant Specialists

The team at Hair Transplant Specialists (INeedMoreHair.com) in Eagan, MN is ready to help determine whether Alma TED fits a patient’s specific situation. The practice brings together board-certified surgeons with a combined 100-plus years of experience, including Dr. Sharon Keene, former President of the International Society of Hair Restoration Surgery.

A consultation here goes beyond a single treatment recommendation. The team assesses the full picture of a patient’s hair loss to recommend the most appropriate path, whether that is Alma TED, combination therapy, surgical restoration, or another approach. Alma TED is one part of a comprehensive non-surgical and surgical menu, and patients who do not qualify will still receive clear guidance on the options that are right for them.

Contact:

• Phone: (651) 393-5399
• Website: INeedMoreHair.com
• Office Hours: Monday–Thursday 9:00 AM–5:00 PM, Friday 9:00 AM–3:00 PM, weekends by appointment

As the practice puts it, “it’s not just about the procedure; it’s about you and your journey.” A consultation is the beginning of a supported, personalized hair restoration experience.